Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-DP in chronic allergic conjunctivitis
NCT02062905Phase 2Completed
- Sponsor
- Ocular Therapeutix
- Start
- Mar 2014
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in allergic conjunctivitis (AC) comparing OTX-DP with Placebo Vehicle (2 arms). Primary endpoint: Ocular Itching at 14 days. Started Mar 2014; status: completed.
02
Drugs
dexamethasone
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02062905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062905.